TE_126
Basic information Differential Expression Stage analysis Survival analysis Correlation analysis| TE family | MLT1F2 |
|---|---|
| TE superfamily | MaLR |
| TE class | LTR |
| Gene | KAZN-AS1 |
| Class | Chimeric |
| Coding | Non-coding |
| Tumor-specific score | 1.19 |
| Counts of samples | TCGA_tumor:100; TCGA_normal:2; GTEx:93 |
| TSS | chr1(-):14362170 |
Transcript isoforms
| Transcript_ID | Gene | Class | Coding | ORF | Position |
|---|---|---|---|---|---|
| teRNA_126.1 | KAZN-AS1 | Chimeric | Non-coding | Non-coding | chr1(-):14338998,14339018,14346236,14346470,14348475,14348565,14350869,14351025,14362113,14362171 |
| teRNA_126.2 | KAZN-AS1 | Chimeric | Non-coding | Non-coding | chr1(-):14349358,14349378,14350869,14351025,14362113,14362171 |
1
GTEx
The proportion of samples in which the TE-initiated transcript was expressed across 46 body sites in the Genotype-Tissue Expression (GTEx) project.
TCGA
The proportion of samples in which the TE-initiated transcript was expressed across 33 cancer types from The Cancer Genome Atlas (TCGA).
GTEx
The expression of TE-initiated transcript across 46 body sites from The Genotype-Tissue Expression (GTEx) project.
